Subject(s)
Coronavirus Infections , Disclosure , Infection Control , Pandemics , Pneumonia, Viral , Politics , Public Policy , Betacoronavirus , COVID-19 , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Coronavirus Infections/transmission , Decision Making , Humans , Infection Control/methods , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control , Pneumonia, Viral/transmission , Quarantine , SARS-CoV-2 , Time Factors , United States/epidemiologySubject(s)
Coronavirus Infections , Critical Care/organization & administration , Delivery of Health Care/organization & administration , Epidemics , Health Workforce , Pneumonia, Viral , State Medicine/organization & administration , Betacoronavirus , COVID-19 , Coronavirus Infections/diagnosis , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Equipment and Supplies, Hospital , Hospitals , Humans , Pneumonia, Viral/diagnosis , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control , SARS-CoV-2 , United Kingdom/epidemiologySubject(s)
Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Pneumonia, Viral/epidemiology , COVID-19 , Caribbean Region/epidemiology , Central America/epidemiology , Chile/epidemiology , Comorbidity , Coronavirus Infections/prevention & control , Humans , Latin America/epidemiology , Mexico/epidemiology , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Politics , PovertySubject(s)
Abattoirs , Coronavirus Infections/epidemiology , Meat-Packing Industry , Pneumonia, Viral/epidemiology , Betacoronavirus , COVID-19 , Communicable Disease Control/methods , Coronavirus Infections/prevention & control , Humans , Occupational Exposure , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , SARS-CoV-2Subject(s)
Coronavirus Infections , Decision Making , Health Planning , Health Policy , International Cooperation , Pandemics , Pneumonia, Viral , Betacoronavirus , COVID-19 , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Europe/epidemiology , European Union , Ezetimibe, Simvastatin Drug Combination , Forecasting , Guidelines as Topic , Humans , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control , SARS-CoV-2 , Time Factors , United KingdomSubject(s)
Coronavirus Infections/prevention & control , Pandemics/prevention & control , Personal Protective Equipment/supply & distribution , Pneumonia, Viral/prevention & control , Purchasing, Hospital/statistics & numerical data , Betacoronavirus/isolation & purification , COVID-19 , Coronavirus Infections/epidemiology , Coronavirus Infections/mortality , Coronavirus Infections/virology , England/epidemiology , Equipment and Supplies, Hospital/statistics & numerical data , Equipment and Supplies, Hospital/supply & distribution , Government Employees/legislation & jurisprudence , Humans , Personal Protective Equipment/trends , Pneumonia, Viral/epidemiology , Pneumonia, Viral/mortality , Pneumonia, Viral/virology , SARS-CoV-2 , State Medicine/organization & administrationSubject(s)
Communicable Diseases, Emerging/epidemiology , Communicable Diseases, Emerging/prevention & control , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Coronavirus/isolation & purification , Disaster Planning/legislation & jurisprudence , Global Health , Guideline Adherence/legislation & jurisprudence , Pandemics/prevention & control , China/epidemiology , Communicable Diseases, Emerging/virology , Coronavirus Infections/virology , Disaster Planning/organization & administration , Global Health/legislation & jurisprudence , Guideline Adherence/organization & administration , Humans , PoliticsSubject(s)
Coronavirus Infections , Masks , Pandemics , Pneumonia, Viral , Public Health , Betacoronavirus , COVID-19 , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Coronavirus Infections/transmission , Evidence-Based Medicine , Guidelines as Topic , Humans , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control , Pneumonia, Viral/transmission , Review Literature as Topic , SARS-CoV-2Subject(s)
Allergy and Immunology/trends , Animals, Domestic/immunology , Animals, Wild/immunology , Communicable Diseases, Emerging/immunology , Communicable Diseases, Emerging/prevention & control , Ecosystem , Animals , COVID-19 , Chiroptera , Communicable Diseases, Emerging/veterinary , Coronavirus Infections/immunology , Coronavirus Infections/prevention & control , Coronavirus Infections/veterinary , Disease Models, Animal , Humans , Immune System , Pandemics/prevention & control , Pandemics/veterinary , Pneumonia, Viral/immunology , Pneumonia, Viral/prevention & control , Pneumonia, Viral/veterinarySubject(s)
Coronavirus Infections/prevention & control , Disclosure , Health Personnel , Pandemics/prevention & control , Personal Protective Equipment/supply & distribution , Pneumonia, Viral/prevention & control , Betacoronavirus , COVID-19 , Coronavirus Infections/transmission , Health Resources , Humans , Pneumonia, Viral/transmission , Practice Guidelines as Topic , SARS-CoV-2Subject(s)
Breast Feeding , Coronavirus Infections , Infection Control/methods , Milk, Human , Pandemics , Pneumonia, Viral , Pregnancy Complications, Infectious , Psychosocial Support Systems , Betacoronavirus/immunology , Betacoronavirus/isolation & purification , Breast Feeding/methods , Breast Feeding/psychology , COVID-19 , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Coronavirus Infections/transmission , Female , Humans , Infant, Newborn , Infectious Disease Transmission, Vertical/prevention & control , Male , Milk, Human/immunology , Milk, Human/virology , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control , Pneumonia, Viral/transmission , Postnatal Care/methods , Postnatal Care/trends , Pregnancy , Pregnancy Complications, Infectious/epidemiology , Pregnancy Complications, Infectious/prevention & control , SARS-CoV-2 , United StatesABSTRACT
A novel coronavirus (severe acute respiratory syndrome-CoV-2) that initially originated from Wuhan, China, in December 2019 has already caused a pandemic. While this novel coronavirus disease (COVID-19) frequently induces mild diseases, it has also generated severe diseases among certain populations, including older-aged individuals with underlying diseases, such as cardiovascular disease and diabetes. As of 31 March 2020, a total of 9786 confirmed cases with COVID-19 have been reported in South Korea. South Korea has the highest diagnostic rate for COVID-19, which has been the major contributor in overcoming this outbreak. We are trying to reduce the reproduction number of COVID-19 to less than one and eventually succeed in controlling this outbreak using methods such as contact tracing, quarantine, testing, isolation, social distancing and school closure. This report aimed to describe the current situation of COVID-19 in South Korea and our response to this outbreak.
Subject(s)
Betacoronavirus/pathogenicity , COVID-19/epidemiology , COVID-19/transmission , Communicable Disease Control/organization & administration , Coronavirus Infections/epidemiology , Coronavirus Infections/transmission , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/transmission , Quarantine/organization & administration , Basic Reproduction Number , COVID-19/prevention & control , Coronavirus Infections/prevention & control , Epidemiological Monitoring , Evidence-Based Medicine , Human Activities , Humans , Physical Distancing , Pneumonia, Viral/prevention & control , Republic of Korea/epidemiology , SARS-CoV-2 , TravelSubject(s)
Coronavirus Infections , Drug Repositioning , Pandemics , Pneumonia, Viral , Viral Vaccines , Betacoronavirus , COVID-19 , COVID-19 Vaccines , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Drug Design , Drug Discovery , Humans , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control , SARS-CoV-2 , Spike Glycoprotein, Coronavirus/drug effectsSubject(s)
Betacoronavirus , Civil Defense , Coronavirus Infections , Internationality , Pandemics , Pneumonia, Viral , Public Health , Public Policy , Asia , COVID-19 , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Disaster Planning , Humans , Hygiene , Information Dissemination , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control , Politics , Quarantine , Risk , SARS-CoV-2 , TravelSubject(s)
Communicable Disease Control/trends , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Occupational Health , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control , COVID-19 , Elective Surgical Procedures/statistics & numerical data , Female , Hospitalization/statistics & numerical data , Humans , Iran , Male , Practice Patterns, Physicians' , Risk Assessment , Urologic Neoplasms/surgery , Urologists/statistics & numerical dataABSTRACT
Porcine deltacoronavirus (PDCoV) causes diarrhea and vomiting in neonatal piglets worldwide and has the potential for cross-species transmission. Therefore, virus-like particles (VLPs) are promising vaccine candidates because of their safety and strong immunogenicity. To the best of our knowledge, the present study reported for the first time the generation of PDCoV VLPs using a baculovirus expression vector system, and electron micrograph analyses revealed that PDCoV VLPs appeared as spherical particles with a diameter similar to that of the native virions. Furthermore, PDCoV VLPs effectively induced mice to produce PDCoV-specific IgG and neutralizing antibodies. In addition, VLPs could stimulate mouse splenocytes to produce high levels of cytokines IL-4 and IFN-γ. Moreover, the combination of PDCoV VLPs and Freund's adjuvant could improve the level of the immune response. Together, these data showed that PDCoV VLPs could effectively elicit humoral and cellular immunity in mice, laying a solid foundation for developing VLP-based vaccines to prevent PDCoV infections.
Subject(s)
Coronavirus Infections , Coronavirus , Swine Diseases , Animals , Mice , Swine , Baculoviridae/genetics , Antibodies, Neutralizing , Coronavirus/genetics , Immunity , Coronavirus Infections/prevention & control , Coronavirus Infections/veterinaryABSTRACT
Avian infectious bronchitis (IB) is a highly contagious disease caused by infectious bronchitis virus (IBV). Vaccination is an effective approach for controlling IBV. Therefore, reliable immune monitoring for IB is critical for poultry. In this study, a novel peptide derived from S2 protein was used to develop an enzyme-linked immunosorbent assay (ELISA) for the detection of broadly cross-reactive antibodies against IBV. The peptide-based ELISA (pELISA) showed good specificity and sensitivity in detecting IBV antibodies against different serotypes. A semilogarithmic regression method for determining IBV antibody titers was also established. Antibody titers detected by pELISA and calculated with this equation were statistically similar to those evaluated by indirect fluorescence assay (IFA). Moreover, the comparison analysis showed a 96.07% compatibility between the pELISA and IDEXX ELISA. All these data demonstrate that the pELISA generated here can be as a rapid and reliable serological surveillance tool for monitoring IBV infection or vaccination.